• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Research Online
    • Conference outputs
    • View Item
    • Home
    • Griffith Research Online
    • Conference outputs
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • Tofacitinib Improves Composite Endpoint Measures of Disease in Patients with Psoriatic Arthritis

    Author(s)
    Helliwell, P
    Coates, LC
    FitzGerald, O
    Nash, P
    Soriano, ER
    Husni, E
    Hsu, M-A
    Kanik, KS
    Hendrikx, T
    Wu, J
    Kudlacz, E
    Griffith University Author(s)
    Nash, Peter
    Year published
    2018
    Metadata
    Show full item record
    Abstract
    Aim To examine the effects of tofacitinib, an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA), on composite endpoints in patients with PsA. Method In two Phase (P)3 studies, patients had active PsA and inadequate response (IR) to ≥1 csDMARD and were TNFi‐naïve (OPAL Broaden [N=422; 12 months; NCT01877668]), or IR to ≥1 TNFi (OPAL Beyond [N=394; 6 months; NCT01882439]). Patients were randomised to tofacitinib 5 mg BID, tofacitinib 10 mg BID, placebo (advancing to tofacitinib 5 or 10 mg BID at Month [M]3) or adalimumab 40 mg subcutaneous injection Q2W (OPAL Broaden only), with a single, stable ...
    View more >
    Aim To examine the effects of tofacitinib, an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA), on composite endpoints in patients with PsA. Method In two Phase (P)3 studies, patients had active PsA and inadequate response (IR) to ≥1 csDMARD and were TNFi‐naïve (OPAL Broaden [N=422; 12 months; NCT01877668]), or IR to ≥1 TNFi (OPAL Beyond [N=394; 6 months; NCT01882439]). Patients were randomised to tofacitinib 5 mg BID, tofacitinib 10 mg BID, placebo (advancing to tofacitinib 5 or 10 mg BID at Month [M]3) or adalimumab 40 mg subcutaneous injection Q2W (OPAL Broaden only), with a single, stable csDMARD. Composite endpoints assessed: Psoriatic Arthritis Disease Activity Score (PASDAS), Disease Activity Score using 28 joints with C‐reactive protein (DAS28‐3[CRP]), Disease Activity Index for Reactive Arthritis/Psoriatic Arthritis (DAREA/DAPSA) and Composite Psoriatic Disease Activity Index (CPDAI) score. Result Mean baseline values were generally similar across treatment arms and studies (OPAL Broaden/Beyond: PASDAS, 5.92–6.03/5.97–6.43; DAS28‐3[CRP], 4.38–4.56/4.40–4.67; DAREA/DAPSA, 38.52–45.55/42.64–51.54; CPDAI, 9.7–10.0/9.6–10.7). Both tofacitinib doses improved composite endpoints vs placebo at M3 in both studies. Effect size among composite endpoints (based on patients with available data for all endpoints) was highest for PASDAS and typically lowest for DAREA/DAPSA; this rank order of effect size was similar across treatment arms and studies. At M3 in OPAL Broaden/Beyond, respectively, effect sizes in tofacitinib‐treated patients ranged from 0.90/0.81 (both DAREA/DAPSA, 5 mg BID) to 2.40/1.84 (both PASDAS, 10 mg BID). Standardised response means generally followed the same pattern as effect size across studies and tofacitinib doses. Conclusions In two P3 studies, tofacitinib 5 and 10 mg BID improved composite endpoint scores vs placebo over 3 months in patients with PsA. Effect sizes and standardised response means were highest for PsA‐specific composite measures and were consistent across studies.
    View less >
    Conference Title
    Internal Medicine Journal
    Volume
    48
    Issue
    S4
    Publisher URI
    https://onlinelibrary.wiley.com/doi/10.1111/imj.13772
    Subject
    Cardiorespiratory Medicine and Haematology
    Clinical Sciences
    Public Health and Health Services
    Science & Technology
    Life Sciences & Biomedicine
    Medicine, General & Internal
    General & Internal Medicine
    Publication URI
    http://hdl.handle.net/10072/402505
    Collection
    • Conference outputs

    Footer

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E

    Tagline

    • Gold Coast
    • Logan
    • Brisbane - Queensland, Australia
    First Peoples of Australia
    • Aboriginal
    • Torres Strait Islander